Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spleen Aminopeptide Oral Solution for prevention and treatment of seasonal allergic rhinitis in children
ChiCTR2400084131Phase 4Completed
- Sponsor
- Beijing No. 1 Biochemical Pharmaceutical
- Start
- Apr 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of spleen polypeptide in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Beijing No. 1 Biochemical Pharmaceutical. Primary endpoint: Symptom score at 12 weeks. Started Apr 2024; status: completed.
02
Drugs
spleen polypeptide
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on ChiCTR2400084131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084131.